These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 17241530

  • 1. Pharmacokinetic characteristics of L-valyl-ara-C and its implication on the oral delivery of ara-C.
    Cheon EP, Han HK.
    Acta Pharmacol Sin; 2007 Feb; 28(2):268-72. PubMed ID: 17241530
    [Abstract] [Full Text] [Related]

  • 2. Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells.
    Cheon EP, Hong JH, Han HK.
    J Pharm Pharmacol; 2006 Jul; 58(7):927-32. PubMed ID: 16805952
    [Abstract] [Full Text] [Related]

  • 3. Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine.
    Sun Y, Sun J, Shi S, Jing Y, Yin S, Chen Y, Li G, Xu Y, He Z.
    Mol Pharm; 2009 Jul; 6(1):315-25. PubMed ID: 19115956
    [Abstract] [Full Text] [Related]

  • 4. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
    Matsushita T, Ryu EK, Hong CI, MacCoss M.
    Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K, Tsuruo T, Naganuma K, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [Abstract] [Full Text] [Related]

  • 6. High-performance liquid chromatography/tandem mass spectrometry method for the simultaneous determination of cytarabine and its valyl prodrug valcytarabine in rat plasma.
    Sun Y, Sun J, Wen B, Shi S, Xu Y, Chen Y, Wang Y, Pan C, Zhang C, Zhang T, He Z.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul 01; 870(1):121-5. PubMed ID: 18571482
    [Abstract] [Full Text] [Related]

  • 7. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
    Yang JZ, Chen W, Borchardt RT.
    J Pharmacol Exp Ther; 2002 Nov 01; 303(2):840-8. PubMed ID: 12388671
    [Abstract] [Full Text] [Related]

  • 8. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and investigation of N4-substituted cytarabine derivatives as prodrugs.
    Fadl TA, Hasegawa T, Youssef AF, Farag HH, Omar FA, Kawaguchi T.
    Pharmazie; 1995 Jun 01; 50(6):382-7. PubMed ID: 7651974
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the conjugate between N4-(4-carboxybutyryl)-1-beta-D-arabinofuranosylcytosine and chitosan as a macromolecular prodrug of 1-beta-D-arabinofuranosylcytosine.
    Ichikawa H, Onishi H, Takahata T, Machida Y, Nagai T.
    Drug Des Discov; 1993 Jun 01; 10(4):343-53. PubMed ID: 8148473
    [Abstract] [Full Text] [Related]

  • 11. Prodrugs of perzinfotel with improved oral bioavailability.
    Baudy RB, Butera JA, Abou-Gharbia MA, Chen H, Harrison B, Jain U, Magolda R, Sze JY, Brandt MR, Cummons TA, Kowal D, Pangalos MN, Zupan B, Hoffmann M, May M, Mugford C, Kennedy J, Childers WE.
    J Med Chem; 2009 Feb 12; 52(3):771-8. PubMed ID: 19146418
    [Abstract] [Full Text] [Related]

  • 12. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J, Kataoka T, Tsukagoshi S, Sakurai Y, Shibukawa M, Kobayashi H.
    Cancer Res; 1981 Jun 12; 41(6):2501-6. PubMed ID: 7237444
    [Abstract] [Full Text] [Related]

  • 13. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
    El-Kamel AH, Abdel-Aziz AA, Fatani AJ, El-Subbagh HI.
    Int J Pharm; 2008 Jun 24; 358(1-2):248-55. PubMed ID: 18502065
    [Abstract] [Full Text] [Related]

  • 14. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies.
    Kim BY, Doh HJ, Le TN, Cho WJ, Yong CS, Choi HG, Kim JS, Lee CH, Kim DD.
    Int J Pharm; 2005 Apr 11; 293(1-2):193-202. PubMed ID: 15778057
    [Abstract] [Full Text] [Related]

  • 15. Stability of valacyclovir: implications for its oral bioavailability.
    Granero GE, Amidon GL.
    Int J Pharm; 2006 Jul 06; 317(1):14-8. PubMed ID: 16759825
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration.
    Yang YW, Lee JS, Kim I, Jung YJ, Kim YM.
    Eur J Pharm Biopharm; 2007 May 06; 66(2):260-7. PubMed ID: 17182232
    [Abstract] [Full Text] [Related]

  • 20. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
    Rauko P, Bauer W, Horvath Z, Höchtl T, Saiko P, Karl D, Schott H, Fritzer-Szekeres M, Novotny L, Szekeres T.
    Anticancer Res; 2003 May 06; 23(5A):3841-6. PubMed ID: 14666686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.